LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,892 | -38.7% | 10,925 | -26.8% | 0.00% | -20.0% |
Q2 2023 | $21,044 | -36.0% | 14,925 | -31.9% | 0.01% | -44.4% |
Q1 2023 | $32,888 | -30.4% | 21,925 | -26.7% | 0.01% | -35.7% |
Q4 2022 | $47,282 | +63.0% | 29,925 | +20.1% | 0.01% | +55.6% |
Q3 2022 | $29,000 | -39.6% | 24,925 | -16.7% | 0.01% | -35.7% |
Q2 2022 | $48,000 | 0.0% | 29,925 | -3.2% | 0.01% | +16.7% |
Q1 2022 | $48,000 | -38.5% | 30,925 | -3.1% | 0.01% | -33.3% |
Q4 2021 | $78,000 | +8.3% | 31,925 | +10.4% | 0.02% | 0.0% |
Q3 2021 | $72,000 | -12.2% | 28,925 | -0.3% | 0.02% | -14.3% |
Q2 2021 | $82,000 | +9.3% | 29,000 | -9.4% | 0.02% | 0.0% |
Q1 2021 | $75,000 | +36.4% | 32,000 | +3.2% | 0.02% | +31.2% |
Q4 2020 | $55,000 | +2650.0% | 31,000 | +6.9% | 0.02% | – |
Q3 2020 | $2,000 | -92.0% | 29,000 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $25,000 | 0.0% | 29,000 | -5.5% | 0.01% | -25.0% |
Q1 2020 | $25,000 | +31.6% | 30,700 | +44.8% | 0.01% | +71.4% |
Q4 2019 | $19,000 | +5.6% | 21,200 | +16.5% | 0.01% | 0.0% |
Q3 2019 | $18,000 | – | 18,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |